The US FDA announced it is expanding its investigation into the broader field of PD-1/PD-L1 cancer drugs more than a month after the news of a clinical hold on three of Merck & Co. Inc.'s multiple myeloma clinical trials for Keytruda (pembrolizumab).
Merck announced the hold July 5, pausing three combination trials of Keytruda with Celgene Corp.'s immunomodulatory thalidomide analogues Pomalyst...




